Ludwig In the News

August 10, 2022
The ASCO Post

Ludwig Cancer Research recently announced the appointment of Pat Morin as deputy scientific director of the Ludwig Institute for Cancer Research.

June 20, 2022
Oncology Times

In an interview with Oncology Times, Ludwig Princeton Director Joshua Rabinowitz discussed the findings of a study he published in the journal Med showing that a ketogenic diet with chemotherapy tripled survival time compared with chemotherapy alone in mouse models of pancreatic ductal adenocarcinoma.

June 16, 2022
New Jersey Business Magazine

Ludwig Princeton Associate Director Eileen White has been selected as a team leader for a $25 million Cancer Grand Challenges award to tackle cachexia, a debilitating wasting condition associated with advanced cancers that worsens patient prognosis and quality of life.

June 4, 2022
Science

Researchers co-led by Ludwig Johns Hopkins scientists, their colleagues at Johns Hopkins University and Ludwig alumni at WEHI, in Melbourne, Australia reported at the 2022 ASCO Annual Meeting that circulating tumor DNA (ctDNA) — genetic material shed from tumors into the bloodstream — can identify stage II colon cancer patients who can most benefit from chemotherapy following surgery and spare other patients the need for this form of treatment.

May 26, 2022
Nature Asia

Ludwig Harvard’s Kai Wucherpfennig published a study in Nature reporting the design and preclinical evaluation in mice and primates of a new type of cancer vaccine that could be of nearly universal utility to cancer patients.

May 5, 2022
CQFD

In this radio interview, Alexandra Richard of CQFD speaks with Lana Kandalaft (in French) about clinical trials at Ludwig Lausanne evaluating individualized dendritic cell vaccines for the treatment of lung, pancreatic and, soon, ovarian cancers.

April 10, 2022
USA Today*

This article covers the story and promising findings of an ongoing clinical trial led by Ludwig Stanford’s Michelle Monje and Crystal Mackall of a novel immunotherapy for universally lethal H3K27M-mutated diffuse midline gliomas.

March 20, 2022
Johns Hopkins Magazine – Spring 2022

This profile of Bert Vogelstein and Ken Kinzler, co-directors of Ludwig Johns Hopkins, tells the story of their long partnership and outsize contributions to cancer genomics and its application to cutting edge diagnostics and therapies.

March 1, 2022
Krebsforschung Schweiz

In this brief interview (in French), Ludwig Lausanne’s Johanna Joyce discusses her research on glioblastoma, her laboratory’s current focus in that area and what most motivates her in her work.

February 28, 2022
Heidi News*

This article, which is in French, reports on cancer vaccine trials underway involving Ludwig Lausanne researchers Lana Kandalaft, Michal Bassani-Sternberg and Alexandre Harari.

February 15, 2022
Daily Guardian

This study, led by Ludwig Princeton Branch Director Joshua Rabinowitz, shows that a ketogenic diet synergizes with chemotherapy to triple survival time compared to chemotherapy alone in rigorous mouse models of pancreatic ductal adenocarcinoma (PDAC).

January 24, 2022
Forbes

A team of researchers led by Ludwig Stanford’s Michelle Monje discovered that the brain fog associated with long-COVID shares many features with cancer therapy-related cognitive impairment (CRCI).

January 22, 2022
Thanh Nien

In this interview, which is in Vietnamese, Ludwig Scientific Director Chi Van Dang discusses his family, what drew him to medicine and cancer research and the state of cancer care in the U.S. and Vietnam. Dang also shares his current efforts and plans to support biomedical research and medical training in Vietnam.

January 18, 2022
PharmaPhorum

Cancer Research UK, Vaccitech and Ludwig Cancer Research announced the first patient dosed in the MAGE trial, which is testing a novel immunotherapeutic, VTP-600, in patients with the most common type of lung cancer. The trial follows promising preclinical research in mouse models by Benoit Van den Eynde’s group at Ludwig Oxford.

Notice
?

You are now leaving Ludwig Cancer Research's website and are going to a website that is not operated by the association. We are not responsible for the content or availability of linked sites. Do you wish to continue?

Continue
Cancel